Background: Leptomeningeal metastases (LM) are associated with limited survival and treatment options. While involved-field radiotherapy is effective for local palliation, it lacks durability. We evaluated the toxicities of proton craniospinal irradiation (CSI), a treatment encompassing the entire central nervous system (CNS) compartment, for patients with LM from solid tumors.
Methods: We enrolled patients with LM to receive hypofractionated proton CSI in this phase I prospective trial. The primary endpoint was to describe treatment-related toxicity, with dose-limiting toxicity (DLT) defined as any radiation-related grade 3 non-hematologic toxicity or grade 4 hematologic toxicity according to the Common Terminology Criteria for Adverse Events that occurred during or within 4 weeks of completion of proton CSI. Secondary endpoints included CNS progression-free survival (PFS) and overall survival (OS).
Results: We enrolled 24 patients between June 2018 and April 2019. Their median follow-up was 11 months. Twenty patients were evaluable for protocol treatment-related toxicities and 21 for CNS PFS and OS. Two patients in the dose expansion cohort experienced DLTs consisted of grade 4 lymphopenia, grade 4 thrombocytopenia, and/or grade 3 fatigue. All DLTs resolved without medical intervention. The median CNS PFS was 7 months (95% CI: 5-13) and the median OS was 8 months (95% CI: 6 to not reached). Four patients (19%) were progression-free in the CNS for more than 12 months.
Conclusion: Hypofractionated proton CSI using proton therapy is a safe treatment for patients with LM from solid tumors. We saw durable disease control in some patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850116 | PMC |
| http://dx.doi.org/10.1093/neuonc/noaa152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic Degradation of Durable Polymer Networks by Light and Acid Enabled by Pyrenylsilicon Crosslinks.
Adv Mater
December 2024
Department of Basic Science, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1, Komaba, Meguro-ku, Tokyo, 153-8902, Japan.
Material photocontrol has gained importance in process engineering and biomedical applications. However, highly photoreactive materials are intrinsically unstable to light, which limits their continuous use in lit environments owing to their gradual deterioration. Herein, synergistically photocontrollable materials in the presence of acid are developed to overcome the conventional trade-off between their photoreactivity and photostability.
View Article and Find Full Text PDFIntensive pediatric chemotherapy regimen (PNET HR+5) in adult high-risk medulloblastoma and pineoblastoma patients.
Neurooncol Adv
August 2024
Department of Medical Oncology, Centre Leon Bérard, Lyon, France (L.L., A.B.-L., D.F.).
Background: High-risk medulloblastoma (HRMB) is rare in adults. The 5-year overall survival rate is less than 60%. We present here a retrospective analysis of adults treated with an intensive pediatric chemo-radiotherapy regimen PNET HR + 5: NCT00936156.
View Article and Find Full Text PDFCase report: successful treatment of primary intradural extramedullary extraskeletal Ewing sarcoma in adult patient with intralesional surgery, chemotherapy, and proton beam therapy of the cerebrospinal axis.
Ther Adv Med Oncol
November 2024
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, Warsaw 02-781, Poland.
Ewing sarcoma is a rare malignant neoplasm that primarily affects bone in children. Extraskeletal location is less common, while intradural extramedullary Ewing sarcoma (IEES) in adults is a casuistic phenomenon. Due to its rarity, a standardized treatment strategy for IEES has not been established.
View Article and Find Full Text PDFCraniospinal irradiation using pencil beam Scanning: The PSI experience.
Phys Med
November 2024
Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232 Villigen, Switzerland; Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Radiation Oncology, University Hospital of Zürich, Zürich, Switzerland.
Article Synopsis
- The study evaluated craniospinal irradiation (CSI) treatments using protons at the Paul Scherrer Institute, focusing on local recurrences and late toxicity outcomes for 71 patients, mostly children and young adults with tumors like medulloblastoma and ependymoma.
- Data from patients treated in both prone and supine positions were analyzed, revealing that supine positioning led to lower systematic and random errors in treatment setup, resulting in more accurate dosing.
- The research concluded that local failures in treatment were not linked to inaccuracies in radiation dosing, and there was no observed correlation between treatment-related toxicities and increased radiation effects.
Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.
Radiat Oncol
October 2024
Department of Pediatric Radiation Therapy Center/Pediatric Proton Beam Therapy Center, Hebei Yizhou Cancer Hospital, Zhuozhou, 072750, China.
Article Synopsis
- This report highlights the case of a male patient who developed a second glioblastoma 32 years after being treated for medulloblastoma, emphasizing the treatment process and relevant literature.
- The patient underwent successful surgery and was treated with proton beam therapy and Temozolomide, resulting in a complete response after his radiation-induced glioblastoma was diagnosed.
- The discussion includes the importance of molecular profiling in managing second primary tumors like RIGB and underscores the advantages of proton beam therapy for protecting healthy tissue during high-dose treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!